Aligos Therapeutics disclosed new Phase 1 data for pevifoscorvir sodium and non‑clinical data for ALG‑055009 at the HEP‑DART 2025 meeting in Honolulu. The Phase 1 data cover 96 weeks of treatment and post‑treatment follow‑up and were presented by CEO Lawrence Blatt on December 9, 2025. The non‑clinical data were presented on December 10, 2025.
The 96‑week monotherapy data for pevifoscorvir sodium, a capsid assembly modulator for chronic hepatitis B, demonstrate sustained viral suppression and a favorable safety profile. The results support the candidate’s potential as a first‑line therapy and align with the company’s plan to enroll patients in the Phase 2 B‑SUPREME study.
ALG‑055009, a thyroid hormone receptor‑β agonist, showed synergistic weight‑loss effects when combined with incretin receptor agonists. In diet‑induced obese mice, the combination with tirzepatide produced up to 40 % body‑weight reduction, while the combination with semaglutide produced up to 33 % reduction. The weight loss was primarily from fat mass, with no significant impact on lean mass or food intake, indicating a favorable safety profile.
The HBV data reinforce Aligos’s strategy to develop a best‑in‑class HBV therapy, while the metabolic data position the company to capitalize on the growing market for combination obesity and MASH treatments. The company is actively pursuing partnership opportunities for ALG‑055009 to accelerate development and commercialization.
In Q3 2025, Aligos reported a net loss of $31.5 million, up from $19.3 million in Q3 2024, driven by higher R&D spending of $23.9 million versus $16.8 million. Revenue fell to $0.741 million from $1.25 million, reflecting lower sales of existing products. Cash and equivalents stood at $99.1 million, providing runway into Q3 2026. The company’s financial profile underscores the importance of progressing its pipeline to generate future revenue.
CEO Lawrence Blatt emphasized the excitement around the HBV and metabolic data, noting that the combination approach aligns with industry trends toward multi‑target therapies. He highlighted the company’s commitment to advancing both pipelines while managing costs to preserve cash.
The data were well received by investors, contributing to a broader positive sentiment around Aligos’s pipeline, though the company remains in a highly competitive therapeutic space with established players in both HBV and obesity markets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.